Oxis International to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
Live Webcast, Scheduled Today at 10:20 a.m. Eastern Time, To Include Update on ERGO Program
FOSTER CITY, Calif.--
OXIS International Inc (OTCBB: OXIS), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and neutraceutical and therapeutic products, announced that Marvin S. Hausman MD, its President and CEO, is scheduled to present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference on Monday, May 14, at 4:20 p.m. local time (10:20 a.m. Eastern time). Dr. Hausman is expected to present an update on the Company's L-ergothioneine (ERGO) Program, The conference is being held at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Recently, OXIS announced that its lead antioxidant compound ERGO showed dramatic results in preserving function of sperm cells undergoing freezing and thawing. These experiments were designed by an expert in equine fertility, Lisa Metcalf, MS DVM Diplomate, American College of Theriogenology and executed in independent animal fertility laboratories. ERGO increased sperm cell viability by 15-20% in pre-clinical and clinical studies as measured by total and progressive motility, when added to known cell extender preservatives in general use in the fertility field.
These results dramatically indicate new potential applications for ERGO in various fields in which cell preservation is crucial, including, but not limited to, applications involving stem cells, sperm cells, oocytes (ova), chondrocytes (cartilage), and cell cloning Oxis has filed protective patents to cover these potential new applications for ERGO.
A live webcast of the event is available at http://www.wsw.com/webcast/rrshq11/oxis.ob. A replay of the webcast will be available for 90 days.
About OXIS and BioCheck:
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress associated with damage from free radical and reactive oxygen species and the related increased inflammation that accompanies oxidative stress. OXIS presently holds the rights to three therapeutic classes of compounds in the treatment of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione peroxidase), as well as the super potent antioxidant, Ergothioneine, that is planned to be introduced as an over-the-counter neutraceutical supplement. OXIS's customers include leading pharmaceutical companies such as Pfizer, Glaxo SmithKline and Genzyme and universities such as Baylor College of Medicine, University of Minnesota, Virginia School of Technology, distributors and government laboratories. OXIS has acquired a 51% interest in BioCheck, with the option to purchase the remaining 49%.
BioCheck is a provider of high quality enzyme immunoassay research services and products, and a leading provider of immunoassay kits for cardiac and tumor biomarkers, infectious diseases, thyroid function, steroids, and fertility hormones. BioCheck operates a 15,000 square-foot, U.S. Food and Drug Administration (FDA) certified cGMP, and ISO device-manufacturing facility in Foster City, California.
More information about OXIS, BioCheck and their products, services as well as current SEC filings may be obtained by visiting http://www.oxisresearch.com and http://www.biocheckinc.com.
The statements in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements regarding our expectations, objectives, anticipations, plans, hopes, beliefs, intentions or strategies regarding the future. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties indicated in the company's filings with the Securities and Exchange Commission. It is important to note that actual outcomes could differ materially from those in such forward-looking statements.
Source: OXIS International, Inc.
Released May 14, 2007